Cellaria
Cellaria develops high-quality, patient-specific in vitro disease models for precise medical insights.
Founded
2013Cellaria develops high-quality, patient-specific in vitro disease models for precise medical insights.
Founded with a mission to revolutionize disease research, Cellaria develops high-quality, patient-specific in vitro disease models that capture the unique biological characteristics of individual patients. These models begin with tissue from patients, ensuring clinically relevant details that enhance model characterization. The company's core vision is to provide precise medical insights that drive personalized medicine, targeting researchers and pharmaceutical companies focused on oncology and other complex diseases.
Notable affiliated individuals include experts in biotechnology and personalized medicine. Cellaria has garnered attention from investors committed to advancing healthcare innovations. Key achievements include the successful development of next-generation disease models that have been adopted by leading research institutions and pharmaceutical companies. Overall, Cellaria's impact lies in its contribution to more accurate disease modeling, which facilitates the development of targeted therapies and accelerates the path to personalized treatment solutions.
Companies similar to Cellaria include Xcell Biosciences, Cellularis Biomodels, Antria and OncoPrecision.
Cellaria was founded in 2013.
Cellaria's headquarters is located in Wakefield, MA, US.
Cellaria's most recent funding round was for $150k (USD) in May 2020.
As of May 18, 2020, Cellaria has disclosed funding of $150k (USD). Undisclosed round amounts are excluded.
Cellaria has 12 employees as of Feb 5, 2024.
OncoPrecision
oncoprecision.bio
